Related Experiment Video
Updated: Dec 30, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
8.8K
Pathologically Node-Positive Prostate Cancer: Casting for Cure When the Die Is Cast?
Kevin B Ginsburg1, Michael L Cher1, Alexander Kutikov2
1From the Department of Urology, Wayne State University School of Medicine, Detroit, MI.
Cancer Journal (Sudbury, Mass.)
|January 25, 2020
Summary
Managing prostate cancer with lymph node involvement (pN+) after surgery is complex due to limited data. Treatment strategies vary, impacting patient outcomes and survival rates.
Area of Science:
- Oncology
- Urology
- Cancer Research
Background:
- Postoperative management of lymph node-positive (pN+) prostate cancer lacks robust randomized trial data.
- Clinical courses for pN+ prostate cancer patients are variable, with some progressing rapidly and others experiencing prolonged quiescence.
Purpose of the Study:
- To review current management strategies for pN+ prostate cancer post-radical prostatectomy.
- To evaluate the impact of adjuvant therapies on patient outcomes.
Main Methods:
- Review of retrospective studies and existing randomized trial data.
- Analysis of treatment outcomes based on pathological parameters and disease burden.
Main Results:
- Randomized trials show adjuvant androgen deprivation therapy (ADT) improves survival in pN+ disease.
- Retrospective data suggest adjuvant radiation therapy (RT) may benefit specific patient subgroups.
- Lower lymph node burden may allow for observation and salvage therapy instead of immediate adjuvant ADT/RT.
Conclusions:
- Adjuvant ADT and potentially RT improve outcomes for pN+ prostate cancer patients.
- Treatment decisions should consider individual patient factors, including lymph node disease burden.
- Further research is needed to optimize management strategies for this challenging patient population.
